Woodline Partners’s Definium Therapeutics DFTX Stock Holding History

Woodline Partners’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.2M	Buy	1,003,641 +250,849	+33%	+$6.2M	0.15%	188
2026 Q1	$14.2M	Buy	752,792 +602,222	+400%	+$10.2M	0.05%	423
2025 Q4	$2.02M	Buy	+150,570	New	+$1.86M	0.01%	769
2025 Q3	–	Sell	-502,198	Closed	-$3.26M	–	992
2025 Q2	$3.26M	Sell	502,198 -503,000	-50%	-$3.31M	0.02%	638
2025 Q1	$5.88M	Hold	1,005,198	–	–	0.04%	462
2024 Q4	$7M	Buy	1,005,198 +2,654	+0.3%	+$18.3K	0.05%	421
2024 Q3	$5.7M	Buy	1,002,544 +1,294	+0.1%	+$9K	0.05%	376
2024 Q2	$7.22M	Buy	1,001,250 +671	+0.1%	+$5.87K	0.07%	291
2024 Q1	$9.41M	Buy	+1,000,579	New	+$5.71M	0.09%	280

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Woodline Partners's DFTX Position: Q2 2026 in Review

Woodline Partners increased its Definium Therapeutics (DFTX) stake by 33% in Q2 2026, buying an estimated $6.2M and bringing the position to 1,003,641 shares worth $47.2M. The position accounts for 0.15% of the portfolio, ranked #188.

Woodline Partners first reported a position in DFTX in Q1 2024 and has held it in 9 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Woodline Partners held 1,003,641 shares of Definium Therapeutics worth $47.2M as of Q2 2026.
Woodline Partners bought 250,849 Definium Therapeutics shares in Q2 2026, an estimated $6.2M.
Definium Therapeutics made up 0.15% of Woodline Partners's portfolio in Q2 2026, its #188 holding.
Woodline Partners first reported a position in Definium Therapeutics in Q1 2024 and has held it in 9 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.